Read the case studies below for specific examples of ways we have helped advance our clients' drug development programs.
The development of a novel extraction and derivatization scheme allowed us to simultaneously determine free and covalently bound drug concentrations using a single assay.
Read this case study
The development of a non-traditional internal standard by derivatization allowed our client to maintain their rigorous timeline without resorting to an expensive synthetic effort.
Read this case study
Employing selective extraction in method development enabled the accurate determination of in vivo drug concentration in plasma samples collected during our client’s Phase I trial.
Read this case study
Customizing specimen collection kits for specific clinical trial sampling requirements streamlined our client’s Phase I study and helped ensure that all specimens collected were stabilized, properly labeled, and provided accurate pharmacokinetic data.
Read this case study
Increasing assay sensitivity to determine drug concentration in epithelial lining fluid (ELF) samples allowed our client’s clinical trial to proceed uninterrupted, saving them time and resources.
Read this case study